Zelsuvmi, a first-in-class topical treatment approved for patients with molluscum contagiosum, will be available in the second half of 2024.
The FDA has approved Ligand Pharmaceuticals’ Zelsuvmi (berdazimer) to treat patients with molluscum contagiosum, an infection caused by a poxvirus. It is indicated for patients one year of age and older and is a first-in-class topical drug approved to treat molluscum infections.
Molluscum contagiosum is a contagious infection that presents as mild skin lesions. Within six to 12 months, it typically resolves without scarring but may take as long as four years, according to the CDC. It affects about 6 million people — mostly children — in the United States. Molluscum is transmitted by human contact or via a contaminated object, such as a towel at the pool or an athletic mat.
Zelsuvmi is nitric oxide releasing agent, which has been shown to have antiviral properties. It is expected to be available in the second half of 2024. Pricing information is not yet available. A company spokesperson indicated that they have begun efforts to discuss coverage with payers.
Zelsuvmi was developed by Novan, which filed for bankruptcy in July 2023. Ligand acquired Novan’s berdazimer, the Nitricil technology and the Bayer-partner Sitavig program for $15 million and also agreed to provide up to $15 million in debtor-in-possession financing.
The FDA’s FDA was based on a results of the B-SIMPLE 4 pivotal phase 3 clinical study published in JAMA Dermatology. The multicenter vehicle-controlled, double-blind study enrolled 891 patients that were across 55 clinics in the United States. At the end of 12 weeks, 32.4% of patients in the berdazimer group achieved complete clearance of lesions, compared with 19.7% in the vehicle group.
Adverse event rates were low. The most commonly reported adverse reactions were application site reactions including pain such as burning or stinging sensations, erythema, itching, exfoliation, dermatitis, swelling, erosion, discoloration, vesicles, irritation, and infection.
ICER Identifies 5 Drugs with Unsupported Price Increases
December 12th 2024The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence, with a total of $815 million in added costs to U.S. payers in 2023.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More